TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Strategy fell 7.72% (net) in the quarter compared to -6.35% for the Russell Midcap Growth Index. In the first quarter, markets navigated geopolitical tensions and economic resilience alongside temporary global tariffs. High oil prices and supply chain disruptions followed U.S. and Israeli involvement in Iran, prompting a shift to safer assets and a reevaluation of supply chains and energy dependencies. Central banks maintained steady policies despite energy-driven inflation. In this environment, the Strategy remains focused on disciplined management teams with durable competitive advantages. Please review the Strategy’s top five holdings to gain insights into their key selections for 2026.
In its first-quarter 2026 investor letter, TimesSquare Capital U.S. Mid Cap Growth Strategy highlighted Stevanato Group S.p.A. (NYSE:STVN). Stevanato Group S.p.A. (NYSE:STVN) is an Italian company that designs and distributes products and processes that offer integrated solutions for the biopharma and healthcare industries. On June 30, 2026, Stevanato Group S.p.A. (NYSE:STVN) closed at $18.07 per share. One-month return of Stevanato Group S.p.A. (NYSE:STVN) was -2.48%, and its shares lost 26.18% over the past 52 weeks. Stevanato Group S.p.A. (NYSE:STVN) has a market capitalization of about $4.93 billion.
TimesSquare Capital U.S. Mid Cap Growth Strategy stated the following regarding Stevanato Group S.p.A. (NYSE:STVN) in its Q1 2026 investor letter:
“Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that command premium pricing, or specialized service providers. Stevanato Group S.p.A. (NYSE:STVN) supplies drug containment, drug delivery, and diagnostic solutions to the biopharmaceutical industry. Its shares declined by -32% on market concerns that the shift to oral GLP1 drug formulations could slow growth in injectable products. However, we believe these concerns may be overblown as Stevanato has several multi-year contracts representing strong revenue visibility. “
Stevanato Group S.p.A. (NYSE:STVN) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 21 hedge fund portfolios held Stevanato Group S.p.A. (NYSE:STVN) at the end of the first quarter, up from 15 in the previous quarter. While we acknowledge the risk and potential of Stevanato Group S.p.A. (NYSE:STVN) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Stevanato Group S.p.A. (NYSE:STVN) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Stevanato Group S.p.A. (NYSE:STVN) and shared a bullish thesis on the company. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
